Nintedanib Clonmel

Nintedanib, the active ingredient in Nintedanib Clonmel, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It treats idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and non‑small cell lung cancer when used with docetaxel. GNH USA supplies Nintedanib Clonmel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Nintedanib acts on multiple fibrotic and oncogenic pathways, providing therapeutic benefit in several serious lung conditions. - Idiopathic pulmonary fibrosis (IPF): slows disease progression and reduces decline in lung function. - Systemic sclerosis‑associated interstitial lung disease (SSc‑ILD): helps preserve lung capacity and delays worsening. - Non‑small cell lung cancer (NSCLC) in combination with docetaxel: improves overall survival and response rates.

Nintedanib is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhea: frequent loose stools, often mild to moderate. - Nausea and vomiting: gastrointestinal upset that may affect appetite. - Abdominal pain: discomfort in the stomach region. - Decreased appetite: reduced desire to eat. - Elevated liver enzymes: mild increases in ALT/AST. - Headache: occasional mild to moderate pain.

Serious or Rare Side Effects: - Severe liver injury: jaundice, hepatitis, or hepatic failure. - Arterial thromboembolism: risk of blood clots in arteries. - Major bleeding: gastrointestinal or intracranial hemorrhage. - Gastrointestinal perforation: rare but serious ulceration. - Severe infections: opportunistic infections in immunocompromised patients. - Lung hemorrhage: rare bleeding within lung tissue.

Before initiating therapy, clinicians should evaluate patient-specific risk factors and monitor key parameters. - Monitor liver function: obtain baseline and periodic ALT/AST measurements. - Assess cardiovascular risk: screen for history of arterial thrombosis. - Watch for gastrointestinal bleeding: especially if patient uses anticoagulants or antiplatelet agents. - Avoid use in severe hepatic impairment: contraindicated in patients with Child‑Pugh C liver disease. - Store at below 25°C: keep in the original pack, protect from moisture and direct sunlight.

Nintedanib may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase nintedanib exposure and toxicity. - Anticoagulants (e.g., warfarin): heighten risk of serious bleeding. - P‑glycoprotein inhibitors (e.g., itraconazole): raise plasma concentrations.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin): reduce nintedanib effectiveness. - Antiplatelet agents (e.g., aspirin): additive bleeding risk. - Diuretics: may exacerbate dehydration from diarrhea, requiring fluid monitoring.